These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 14532138)

  • 41. RA treatment study group: improvement in RA management.
    Ward M; Liang MH; Burns T; Singh G
    Joint Bone Spine; 2009 Jul; 76(4):435-7. PubMed ID: 19541527
    [No Abstract]   [Full Text] [Related]  

  • 42. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of the biologic response modifiers.
    Markenson J
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):15-9. PubMed ID: 17491583
    [No Abstract]   [Full Text] [Related]  

  • 47. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New therapies for rheumatoid arthritis.
    Goldblatt F; Isenberg DA
    Clin Exp Immunol; 2005 May; 140(2):195-204. PubMed ID: 15807842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rheumatoid arthritis.
    Ramsburg KL
    Am J Nurs; 2000 Nov; 100(11):40-3. PubMed ID: 11103634
    [No Abstract]   [Full Text] [Related]  

  • 51. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening.
    Rahman N; Healy C; Flint SR; Stassen LF
    J Clin Rheumatol; 2010 Jun; 16(4):197-9. PubMed ID: 20511984
    [No Abstract]   [Full Text] [Related]  

  • 52. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    Chatzidionysiou K; van Vollenhoven RF
    J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Off-label use of biological therapies in systemic diseases].
    Hachulla E
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
    [No Abstract]   [Full Text] [Related]  

  • 54. [Rheumatoid arthritis today].
    Leuchten N; Aringer M
    Internist (Berl); 2008 Dec; 49(12):1471-80; quiz 1481. PubMed ID: 18985308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 57. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 58. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

  • 59. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.
    Talwalkar SC; Grennan DM; Gray J; Johnson P; Hayton MJ
    Ann Rheum Dis; 2005 Apr; 64(4):650-1. PubMed ID: 15769927
    [No Abstract]   [Full Text] [Related]  

  • 60. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.